Section 2: Selection, Procurement and Distribution
2SPD-011
RIVAROXABAN VERSUS ENOXAPARIN IN TRAUMATOLOGY: A PHARMACO-ECONOMIC STUDY
2SPD-017
ANALYSIS AND MONITORING OF THE WORKLOAD AND FINANCIAL BURDEN OF DISPENSING HIGHCOST MEDICINES WITH ITEM-BASED REIMBURSEMENT IN HUNGARIAN HOSPITAL PHARMACIES
2SPD-034
METHODOLOGICAL ANALYSIS OF PHARMACOECONOMIC STUDIES IN CAR-T: A SYSTEMATIC REVIEW
2SPD-033
Making the case for Prefilled Syringes (PFS): Development and utilisation of an economic model
2SPD-022
RELEVANCE OF UNIVERSAL KIT COMPOSITION AND ECONOMIC VALUE OF NON-USED MEDICAL DEVICES
2SPD-027
Medication storage temperatures inside emergency vehicles A pilot study in a temperate climate country
2SPD-025
ACALABRUTINIB + OBINUTUZUMAB VERSUS IBRUTINIB + OBINUTUZUMAB AS FIRST LINEIN CHRONIC LYMPHOCYTIC LEUKEMIA
2SPD-016
APPLICATION OF FAILURE MODE AND EFFECT ANALYSIS TO IMPROVE CYTOSTATIC DRUG STOCK MANAGEMENT
2SPD-014
APPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE
2SPD-012
IMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY IN REAL LIFE
2SPD-001
HOW CAN WE BEST MANAGE SUPPLY SHORTAGES OF EXCLUSIVELY HUMAN MOLECULES FOR SUBSTITUTION ? THE EXAMPLE OF IMMUNOGLOBULINS
2SPD-031
THE ECONOMIC IMPACT OF ANTIMICROBIAL SHORTAGES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES
2SPD-013
INCREASE IN HEALTHCARE COSTS WITH FIDAXOMICIN INSTEAD OF VANCOMYCINFOR CLOSTRIDIUM DIFFICLIE TREATMENT
2SPD-030
How to assess the impact of medicines shortages in the European Union?
2SPD-029
STABILITY OF NIVOLUMAB SOLUTIONS AFTER TRANSPORT THROUGH PNEUMATIC TUBE SYSTEMS
